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Intracellular signal transduction networks, under the control
of activated cell surface receptors, govern cell functional behaviors such as proliferation, migration, differentiation, and programmed cell death (1). Proper communication between signaling proteins is generally contingent upon noncovalent,
intermolecular interactions, mediated by well conserved protein domains. A key feature of these domains is their modular
nature, which has facilitated the extensive characterization of
their binding affinities and specificities in vitro, as well as the
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construction of “synthetic” signaling proteins with prescribed
function (2). The prototypical and best characterized interaction domains in signaling are the Src homology 2 (SH2)3
domains, which direct interactions of proteins with receptor
tyrosine kinases and other tyrosine-phosphorylated proteins
(3). Receptors of the receptor tyrosine kinase family, which
engage growth factor ligands such as platelet-derived growth
factor (PDGF), are activated through ligand binding, receptor
oligomerization, and autophosphorylation on multiple intracellular residues, which then serve as a scaffold for recruitment
of proteins containing SH2 and analogous domains (4, 5).
Signaling proteins typically contain three or more modular
interaction domains of various types, and therefore the diversity of interactions that might take place in the cell is staggering
(6). Further complicating the problem is the avidity effect,
which tends to promote the cooperative association of different
domains with binding partners in the same multimolecular
complex or subcellular compartment. Other mechanisms of
binding cooperativity might also depend on the modification of
signaling proteins at multiple sites (7). This context-dependent
diversity of interactions is a prime example of what has been
called combinatorial complexity (8). Although kinetic modeling has emerged as a powerful tool in the analysis of signal
transduction networks (9 –11), the very large number of potential state variables that can arise even for combinations of a
handful of proteins has prohibited detailed modeling of signaling interactions. The recent development of rule-based modeling tools (12) has enabled modeling of more complex systems;
in previous work, we used this approach to analyze the function
of the protein-tyrosine phosphatase Shp2 (13), demonstrating
the application of rule-based modeling at the level of modular
protein domains.
In this paper, we present mathematical models and analysis
focused on the interactions between tandem SH2 domains
derived from signal transduction proteins and peptides or proteins bearing two phosphotyrosine-binding sites. Such interactions have been characterized in vitro by a variety of biochemical methods (14 –18), but the various types of complexes that
can form between multivalent binding partners cannot be
resolved, making the measurements potentially difficult to
interpret. Although dual SH2 domains are found in a number of
signaling proteins, including isoforms of phospholipase C, the
aforementioned Shp2, and the nonreceptor tyrosine kinases
3

The abbreviations used are: SH, Src homology; PDGF, platelet-derived
growth factor; PI3K, phosphoinositide 3-kinase; SPR, surface plasmon resonance; ITC, isothermal titration calorimetry.
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Intracellular signal transduction proteins typically utilize
multiple interaction domains for proper targeting, and thus a
broad diversity of distinct signaling complexes may be assembled. Considering the coordination of only two such domains, as
in tandem Src homology 2 (SH2) domain constructs, gives rise to
a kinetic scheme that is not adequately described by simple
models used routinely to interpret in vitro binding measurements. To analyze the interactions between tandem SH2
domains and bisphosphorylated peptides, we formulated
detailed kinetic models and applied them to the phosphoinositide 3-kinase p85 regulatory subunit/platelet-derived growth
factor ␤-receptor system. Data for this system from different
in vitro assay platforms, including surface plasmon resonance,
competition binding, and isothermal titration calorimetry, were
reconciled to estimate the magnitude of the cooperativity characterizing the sequential binding of the high and low affinity
SH2 domains (C-SH2 and N-SH2, respectively). Compared with
values based on an effective volume approximation, the estimated cooperativity is 3 orders of magnitude lower, indicative of
significant structural constraints. Homodimerization of fulllength p85 was found to be an alternative mechanism for high
avidity binding to phosphorylated platelet-derived growth factor receptors, which would render the N-SH2 domain dispensable for receptor binding.

Models of Tandem SH2 Domain Interactions
on search volume considerations.
We address the implications of this
apparent structural constraint in
the context of PI3K recruitment and
activation in cells.
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EXPERIMENTAL PROCEDURES
General Modeling Considerations
and Implementation—Our kinetic
models are executed in the second
generation version of the rule-based
modeling software, BioNetGen (25).
BioNetGen 2 uses a programming
syntax that was described in detail
in the supplemental material of
Barua et al. (13). Graph theoretic
methods are used to automatically
generate a complete set of kinetic
equations (ordinary differential
equations in time) based on a set of
user-specified rules. In this modeling framework, molecules and complexes thereof are called species,
and distinct domains/motifs within
the molecules are called components. Other nomenclature specific
to the models presented here is as
follows. The phosphopeptide has
two components, Y1 and Y2, which
represent phosphorylated Tyr751
740
of the human PDGF
FIGURE 1. Rule-based model of tandem SH2 binding to bisphosphorylated peptide. A, rules for bimolec- and Tyr
ular complex formation and associated rate constants. The dashed lines indicate that the remainder of each ␤-receptor, respectively. The tanspecies is unknown, potentially subject to context-dependent rules. B, ring closure transitions and associated
dem SH2 construct also has two
rate constants. The cooperativity factor  has units of concentration and applies to all such transitions. C, all 10
of the distinct tandem SH2䡠phosphopeptide complexes containing one peptide molecule, as in the case where components, C-SH2 and N-SH2,
the peptide is immobilized at low density. Type I complexes contain one tandem SH2 domain molecule that is corresponding to the C-terminal
singly bound, Type II complexes contain one tandem SH2 domain that is doubly bound forming a ring, and
Type III complexes contain two singly bound tandem SH2 domain molecules. D, classification of chain and ring and more N-terminal SH2 domains
structures containing more than one peptide molecule. Type IV complexes are 1:2 chains, whereas Type V of p85, respectively. The compocomplexes are chains with 2:2 or higher stoichiometry. Type VI complexes are ring structures with 2:2 or higher nents are easily silenced in the
stoichiometry. E, examples of complex structures that can form when dimerization of full-length protein, such
model by removing their correas PI3K p85, are considered.
sponding rules to accommodate
peptides with a single phosphorylaSyk and ZAP70, we focus in particular on the interactions tion site or p85 constructs with only one of the SH2 domains.
between the p85 regulatory subunit of phosphoinositide 3-ki- Each of the four combinations of interactions between phosnase (PI3K) and sequences derived from the PDGF ␤-receptor. photyrosine and SH2 components is assigned a second order
PI3Ks are lipid kinases that are strongly activated by PDGF association rate constant kon and a first order dissociation rate
receptors and by many other cell surface receptors, and they constant koff, which characterize the reversible binding of two
play pivotal roles in cell migration, survival, and proliferation species to form one (Fig. 1A). At equilibrium, it is only the ratio
pathways (19, 20). The interactions of the p85 SH2 domains are of these rate constants that matters, with KD ⫽ koff/kon given in
critical for targeting and allosteric activation of the enzyme in units of molar concentration; incidentally, we used the same
realistic value of kon ⫽ 1 M⫺1 s⫺1 for all interactions and modcells (21–24).
Analysis of the models reconciles various published in vitro els, and koff values were specified according to the correspondp85/phosphopeptide binding studies that have utilized differ- ing KD.
Tandem SH2 domains, such as in the p85 regulatory subunit
ent assay platforms, namely surface plasmon resonance (SPR)
and other solid phase binding assays, competition binding, and of PI3K, engage cognate bisphosphorylated peptides and proisothermal titration calorimetry (ITC). Thus, the consensus teins in a cooperative manner, with binding of one SH2 domain
magnitude of the cooperativity parameter characterizing the facilitating the binding of the other through a ring closure transequential association of the two SH2 domains was evaluated sition (Fig. 1B). These interactions are characterized by a first
and found to be orders of magnitude lower than expected based order association rate constant that is the product of the corre-
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unoccupied SH2 and competitor peptide sites, and four rules
for unimolecular ring closure involving unoccupied SH2 and
competitor peptide sites. In BioNetGen 2, it is possible to set the
maximum number of each molecule type in the generated species. Thus, cross-linking of immobilized sites was prohibited
here by setting the maximum number of immobilized peptide
molecules in a complex to 1, and the potentially infinite sizes of
the chain and ring structures were truncated at a maximum
number of N molecules each of the tandem SH2 and bisphosphorylated competitor peptide per complex. Values of n ⫽ 2, 3,
and 4 were used and found to give nearly identical results.
These models vary in complexity as N is increased, yielding 68,
272, and 1,075 distinct species, respectively.
Model 3: Solution Phase Binding—In this model, both the
tandem SH2 construct and bisphosphorylated peptide are in
solution, as in ITC measurements. The binding rules are the
same as in the immobilized phosphopeptide with competition
model, except that the immobilized peptide is absent. Thus, for
the same value of N as described for Model 2, there are correspondingly fewer distinct species in Model 3 (37, 145, and 629
species for n ⫽ 2, 3, and 4, respectively). As with Model 2, these
values of N produced nearly identical results.
Model 4: Immobilized Phosphopeptide with p85 Dimerization—
This model is a modification of Model 1, in which p85 has an
additional domain that mediates p85 dimerization (Fig. 1E), with
six additional rules. Two of these are for dimerization, one for
when at least one of the p85 molecules binds from solution and
another for when both p85 molecules are bound to the same peptide; in the latter case, the  value for dimerization, dimer, is distinguished from that of 1:1 ring formation (Type II complex),
called SH2. To satisfy the principle of detailed balance, dimer also
applies to the ring closure of peptide-p85-p85 chains via either of
the unoccupied SH2 domains in the second p85 molecule. The
network for this model is comprised of 35 distinct species.

RESULTS
Cooperativity of Tandem SH2/Phosphopeptide Binding as a
Key Determinant of Complex Avidity, Stoichiometry, and Equilibration Time—The simplest model is one in which the phosphopeptide is immobilized, such that complexes contain only
one peptide molecule (Model 1) (Fig. 2). This scenario simulates SPR and other solid phase binding assays and is analogous
to p85 recruitment to the plasma membrane. For simplicity, the
two phosphotyrosine sites are assumed here to be equivalent,
and the C-SH2 and N-SH2 domains are assigned single-site KD
values characteristic of PI3K p85 (50 nM and 1.5 M, respectively) (16 –18, 28). Each SH2 domain by itself exhibits the
expected hyperbolic binding isotherm, with half-maximal
binding at a SH2 concentration equal to its KD and a stoichiometry of 2:1 SH2 molecules/peptide at saturation. By comparison,
the binding isotherm of the tandem construct is altered relative
to that of the higher affinity C-SH2, depending on the value of .
As expected, the change is dramatic when  ⫽ ⬃10 M or
greater, exceeding the KD of the low affinity N-SH2 domain
(Fig. 2A). At tandem SH2 concentrations below the C-SH2 KD,
overall binding is enhanced because of the cooperativity of the SH2
domains in forming stable, Type II ring structures (Fig. 1C), the
effective KD for these structures being given by Equation 1.
VOLUME 283 • NUMBER 12 • MARCH 21, 2008
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sponding kon and a cooperativity parameter , which is the
effective concentration of each free binding site within the same
molecular complex (13, 26), assumed to be the same value for all
ring complexes. If such a site were able to freely search a characteristic volume of 100 nm3 (within a 3-nm radius), that concentration would be ⬃20 mM. A more conservative estimate
would account for the flexibility of the peptide and other structural constraints within the complex (27), and hence we varied
 between 1 M and 1 mM and evaluated its effect on the overall
binding avidity and other aspects of complex formation. As the
value of  is increased, the ring closure interactions become
increasingly favorable, and the overall binding avidity of the
complex is enhanced. The reverse, ring opening rate constant is
given by the corresponding koff. The assumption that only the
forward rate constant is modified affects the binding kinetics
but not the equilibrium.
The kinetic equations were integrated numerically for sufficient time to achieve steady state (104 s, typically). All of the
model codes are available upon request.
Model 1: Immobilized Phosphopeptide—In the simplest
model, the bisphosphorylated peptide is immobilized to a surface or solid matrix, and the tandem SH2 construct binds from
solution. It is assumed that the immobilized peptide is present
at a sufficiently low density, such that bound complexes are
comprised of only one peptide and either one or two tandem
SH2 molecules. The peptide is present at an arbitrarily low concentration (10 pM was used) so that the tandem SH2 domain is
far in excess, with its free concentration approximately equal to
the total. Each of the peptide phosphorylation sites (Y1 or Y2),
if unoccupied, may reversibly bind tandem SH2 from solution
(both SH2 domains must be unoccupied) via C-SH2 or N-SH2;
these four combinations constitute separate rules (Fig. 1A). A
peptide䡠SH2 complex with Y1 or Y2 unoccupied may engage in
reversible ring closure transitions (four separate rules shown in
Fig. 1B). As a result, there are 12 distinct species in this model,
the two unbound molecules and 10 distinct peptide䡠SH2 complexes; the complexes are classified as Type I, II, or III depending on their structure (Fig. 1C).
Model 2: Immobilized Phosphopeptide with Competition—
This model is the same as the previous except that the system
also includes soluble, bisphosphorylated peptide as a competitive inhibitor with respect to tandem SH2 binding to the surface, which allows several types of extended structures to form
(Fig. 1D). Although complexes may contain only one immobilized peptide molecule, any species containing an unoccupied
SH2 domain can combine with any other having an unoccupied
competitor peptide site, and thus molecular chains with more
than one bisphosphorylated peptide molecule may be formed.
Chains comprised of one tandem SH2 and two peptide molecules are classified as Type IV complexes, and chains comprised
of four or more molecules are classified as Type V complexes.
Ring structures containing four or more molecules can also
form; these are classified as Type VI complexes. To simplify
matters, the immobilized peptide is only monophosphorylated
(on Y1, corresponding to Tyr(P)751 of PDGF ␤-receptor),
matching the conditions of the published experiments (17).
Thus, there are only two rules for C-SH2 or N-SH2 binding to
the surface, four rules for binding of two species containing
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Bound fraction ⫽
S free ⫽
FIGURE 2. Binding properties of tandem SH2 constructs to immobilized, bisphosphorylated peptides. Calculations were performed using
Model 1, assuming SH2 domain KD values characteristic of PI3K p85. Constant parameter values were kon,C1 ⫽ kon,C2 ⫽ kon,N1 ⫽ kon,N2 ⫽ 1 M⫺1 s⫺1,
KD,C1 ⫽ KD,C2 ⫽ 50 nM, KD,N1 ⫽ KD,N2 ⫽ 1.5 M. A, equilibrium binding
isotherms. The value of  was varied as indicated. B, structure types of
complexes formed with  ⫽ 100 M (refer to Fig. 1C). C, tandem SH2
binding as a function of time ( ⫽ 100 M), with t ⫽ 100, 200, 500, and
1,000 s.

K D eff ⫽

冉

1
1
1
⫹
 KD,C1KD,N2 KD,C2KD,N1

冊

⫺1

(Eq. 1)

Effective KD values for p85 tandem SH2 binding to the
Tyr(P)740/Tyr(P)751 bisphosphorylated peptide have been
MARCH 21, 2008 • VOLUME 283 • NUMBER 12

Sfree
KD,C1 ⫹ Sfree

b ⫹ 关b2 ⫹ 4c兴1/ 2
2

(Eq. 2)

(Eq. 3)

b ⫽ S T ⫺ KD,Ci ⫺ CT

(Eq. 4)

c ⫽ K D,CiST

(Eq. 5)

Equations 2–5 show that the free SH2 concentration, Sfree,
depends on the total concentrations of both SH2 (ST) and the
peptide competitor (CT) and the KD of C-SH2 binding to the
competitor site (i ⫽ 1 for Tyr(P)751, i ⫽ 2 for Tyr(P)740). It was
assumed that ST was chosen to yield ⬇50% surface occupancy
in the absence of competitor. Hence, good agreement with the
C-SH2 inhibition data were found with ST ⫽ KD,C1 ⫽ 10 nM and
KD,C2 ⫽ 75 nM (Fig. 3A), and those parameter values were kept
the same in Fig. 3B, described below.
JOURNAL OF BIOLOGICAL CHEMISTRY
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reported to lie in the vicinity of 1 nM (16, 18); for the single-site
KD values assumed here, an order of magnitude estimate of  ⫽
⬃30 M is obtained. A somewhat lower estimate ( ⫽ ⬃10 M)
is obtained if KD,C1 and KD,C2 are allowed to adopt different
values spanning the range of 10 –100 nM.
In contrast, at tandem SH2 concentrations above the KD of
C-SH2, overall binding is diminished because the ring structure
reduces the overall stoichiometry of SH2 binding. Indeed, as the
value of  is increased, there is an apparent saturation of binding at 1:1 stoichiometry, and increasingly higher tandem SH2
concentrations are needed to shift the equilibrium from
Type II rings to Type III chain structures with 2:1 stoichiometry (Fig. 2B).
Another consequence of cooperative tandem SH2 binding
is slower binding kinetics (Fig. 2C). For a simple receptor/
ligand system with 1:1 binding stoichiometry, it is well
known that the characteristic time constant for approaching
equilibrium is the inverse of koff(1 ⫹ [L]/KD), where koff is the
dissociation rate constant, and [L] is the free ligand concentration (29). Formation of the Type II ring structure effectively increases the dwell time of the tandem SH2 molecule
on the peptide, thus reducing the overall off rate and slowing
the approach to steady state. Indeed, with the highest values
of  the t1⁄2 for approaching steady state at low concentrations is greater than 5 min, compared with t1⁄2 ⫽ ln 2/koff ⫽
14 s for C-SH2 alone.
Analysis of Tandem SH2/Phosphopeptide Interactions in
Competition Binding Experiments Establishes a Lower Limit on
the Cooperativity Parameter —To further characterize the
cooperativity of tandem SH2/phosphopeptide binding, we analyzed the data of Harpur and colleagues (17), who assessed the
ability of Tyr(P)740, Tyr(P)751, and Tyr(P)740/Tyr(P)751 peptides
to inhibit the binding of various p85 constructs (C-SH2, tandem SH2, as well as full-length) to a SPR chip bearing Tyr(P)751;
this experiment is recapitulated in our Model 2 (Fig. 3). In the
relatively simple case of C-SH2 and monophosphorylated peptide as the competitor, the fractional occupancy of the immobilized peptide sites, assumed to be small in number compared
with the SH2 molecules, is given by Equations 2–5.

Models of Tandem SH2 Domain Interactions

The experiments also showed that whereas each of the
monophosphorylated competitor peptides inhibits C-SH2 and
tandem SH2 binding with roughly the same potency, the
bisphosphorylated competitor peptide is more potent toward
tandem SH2 and full-length p85 binding, indicative of the
cooperative formation of ring structures; the inhibition curve
also exhibited a much steeper dose response (17). Those results
are matched nicely by the Model 2 calculations when the value
of  is much greater than the N-SH2 affinity ( ⫽ ⬃10 M or
greater; Fig. 3B). Interestingly, the shape of the inhibition curve
is not attributable to the multivalent nature of the competitor
binding but rather to the near stoichiometric avidity of the
interaction. When the binding avidity is arbitrarily high, the
fractional occupancy of immobilized peptide (Equations 2–5) is
closely approximated by taking Sfree ⬇ ST ⫺ CT, or Sfree ⬇ 0
when the competitor is in excess (CT ⬎ ST), which produces the
characteristic steepness of the inhibition curve. A dramatic
reduction of ST, to a value well below the effective KD of ring
formation (Equation 1), eliminates this feature (results not
shown); however, doing so would reduce the fractional occu-
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⌬H ⫽ ⌬H CSH2nCSH2 ⫹ ⌬HNSH2nNSH2

(Eq. 6)

This is equivalent to assuming that the induced proximity effect
that distinguishes ring closure from chain extension equilibria
is attributed to a difference in conformational entropy.
At lower values of  (1 and 10 M), the calculated numbers of
high affinity C-SH2 bonds formed with each injection show the
characteristic plateau at low molar ratios, thereafter yielding to
formation of N-SH2 interactions, whereas for higher values of 
(100 M and 1 mM), the plateau is absent (Fig. 4A). Using Equation 6 to calculate the heat release/injection and varying the
ratio of specific enthalpies (⌬HNSH2/⌬HCSH2), only  ⫽
⬃10 –30 M correctly recapitulates the experimentally
observed hump in the heat/injection at molar ratios between
VOLUME 283 • NUMBER 12 • MARCH 21, 2008
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FIGURE 3. Evaluation of competition binding experiments. The calculations were performed using Model 2 (see “Experimental Procedures”). A, inhibition of monovalent p85 C-SH2 domain binding to Tyr(P)751 of PDGF ␤-receptor by different competitor peptides as indicated. Fig. 6A of Ref. 17 was
recapitulated with ST ⫽ KD,C1 ⫽ 10 nM and KD,C2 ⫽ 75 nM, where ST is the total
concentration of C-SH2. B, inhibition of p85 tandem SH2 construct by different competitor peptides as indicated. In the case of the bisphosphorylated
competitor, the value of  is varied as indicated. Fig. 6 (B and C) of Ref. 17
compares favorably with these results when  ⬎ 10 M.

pancy on the surface in the absence of competitor, perhaps to
an unacceptably low level for SPR detection.
Analysis of Tandem SH2/Phosphopeptide Interactions in ITC
Measurements Establishes an Upper Limit on the Cooperativity
Parameter —ITC experiments provide information about
molecular interactions through measurements of heat liberated
upon serial injections of one solution into another (30). O’Brien
and colleagues (18) performed such experiments with fulllength p85, injecting increasing amounts of bisphosphorylated
Tyr(P)740/Tyr(P)751 peptide into the calorimeter; the net
energy change required to maintain the system at constant temperature with each injection was plotted as a function of the
increasing molar ratio of peptide/p85. Two distinct changes in
the heat/injection were observed, one starting at a molar ratio
of ⬇0.5 and another, more dramatic reduction induced at a
molar ratio of ⬇1.0; at a molar ratio of 2.0, the heat released was
near 0, indicating saturation of the SH2 domains. Based on
those molar ratios, a conceptual model was proposed in which
the predominant complex at lower peptide concentrations is
the 2:1 chain (Type III complex), whereas a 1:1 complex
(depicted as a Type II ring) dominates for molar ratios
approaching 1.0 (18).
Our calculated results (Model 3), which allow us to resolve
the various types of complexes, shed additional light on those
conclusions and provide further evidence for the magnitude of
 (Fig. 4). Based on a concentration of 10 M p85 in the calorimeter initially and given that 1.5 nmol of peptide was introduced per injection, achieving a molar ratio of 2.0 after 16 injections of 15 l each (18), the total concentrations of p85 and
peptide after each injection were determined. Thus, the total
peptide concentration increases from 1.2 M after the first
injection up to 16.7 M at the end; the p85 is diluted in the
process, with a final concentration of 8.3 M. Based on those
concentrations, and using the same default KD values from Fig.
2, we determined the net changes in the amounts of complexes
after each injection. Changes in these amounts are related to
changes in enthalpy and thus the amount of energy required to
maintain constant temperature after each injection. For the
sake of simplicity, we adopt a thermodynamic model in which
the enthalpy change (⌬H) is a weighted sum of the numbers of
bonds formed with C-SH2 and N-SH2 (nCSH2 and nNSH2,
respectively), regardless of the structures of the complexes
formed.

Models of Tandem SH2 Domain Interactions

0.5 and 1.0 (Fig. 4B and supplemental Fig. S1). Allowing the
individual KD parameters to adopt various values within
the reported ranges yielded similar results (supplemental
Fig. S1).
Further analysis of the complexes formed revealed that when
the molar ratio is between 0.5 and 1,  ⫽ 1 M produces a
mixture of extended chain structures, whereas  ⫽ 10 M leads
predominantly to the formation of ring structures. In both
cases, there is a shift to 1:2 (Type IV) chains as the molar ratio is
increased above 1.0. In contrast, with  ⫽ 100 M, the shift from
Type III chains to Type II rings proceeds steadily for molar
ratios up to 1.0, and with  ⫽ 1 mM, the Type II ring structure
dominates throughout the hypothetical ITC run (supplemental Fig. S2). Taking the results of this and the previous
sections together, it is suggested that the order of magnitude
value of , characterizing the cooperativity of both SH2
domains of PI3K p85 engaging bisphosphorylated peptides
derived from PDGF ␤-receptor, is 10 M.
To What Extent Can Dimerization of p85 Stabilize p85
Binding to Bisphosphorylated Peptide?—It has been shown
that purified PI3K p85 dimerizes in vitro via a Src homology
3 (SH3) domain/proline-rich sequence interaction, estimated to be of micromolar affinity, perhaps aided by a second, lower affinity interaction (17, 31, 32). These domains
are not present in truncated, p85-derived tandem SH2 constructs, but in the context of full-length p85, we were curious
as to how p85 dimerization might affect p85 interactions
with the bisphosphorylated Tyr(P)740/Tyr(P)751 peptide
(Fig. 5). In the corresponding model, Model 4, p85 dimerization is treated as a single interaction with KD ⫽ 1 M in
solution. As in Model 1, the phosphopeptide is assumed to be
immobilized at low density. Here, the structural constraints
MARCH 21, 2008 • VOLUME 283 • NUMBER 12

governing the formation of Type II rings are distinguished
from those governing ring formation via dimerization of p85
molecules attached to the same peptide chain, characterized
by distinct values of  (SH2 and dimer, respectively). The
principle of detailed balance dictates that dimer also applies
to the cyclization of ring structures via one of the two unoccupied SH2 domains of a p85 molecule already dimerized
with another, peptide-bound p85 molecule.
Assuming a value of SH2 ⫽ 10 M, consistent with the analysis in the previous sections, the calculations show that p85
dimerization can improve binding avidity at low nanomolar
concentrations, but only when rings involving dimers are not
subject to significant constraints; dimer must be in the millimolar range (Fig. 5A). With low values of dimer, comparable with
SH2, the binding avidity is not substantially enhanced beyond
what is achieved through Type II ring formation (compare
with Fig. 2A). Ring structures with dimerized p85 molecules
are found in proportion to the free p85 concentration
squared, which is manifested in the steepness of the binding
isotherm at low p85 concentrations. At p85 concentrations
that are far in excess of the dimerization KD, complexes with
stoichiometry approaching 4:1 (two p85 dimers/peptide) are
found. This model was also adapted to examine the binding
of a p85 variant with the N-SH2 domain deleted (Fig. 5B).
Here, the only ring structure that can form is the 2:1 complex
with the p85 molecules dimerized. Comparing the isotherm
with that of wild-type p85 in Fig. 5A, it is apparent that such
rings are the predominant structure at low concentrations of
p85 if dimer is sufficiently high. Under those conditions, the
N-SH2 domain is dispensable for binding to the bisphosphorylated motif.
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 4. Evaluation of ITC experiments. The calculations were performed using the solution phase binding model (Model 3). In ITC experiments performed
by O’Brien et al. (18), 16 aliquots of bisphosphorylated Tyr(P)751/Tyr(P)740 peptide were added sequentially to a fixed amount of p85 in solution, eventually
reaching a molar ratio of 2.0 peptide molecules/p85. Total p85 and peptide concentrations were determined as described in the main text, and single-site KD
values are as assumed in Fig. 2. The value of  is given above each set of panels. A, net change in the numbers of C-SH2 and N-SH2 bonds formed with each
injection of peptide. B, hypothetical enthalpy change with each injection of peptide, with ⌬HCSH2 ⫽ ⫺60 kJ/mol for C-SH2 bonds, and various ratios of
⌬HNSH2/⌬HCSH2; the curves in gray are with ⌬HNSH2/⌬HCSH2 ⫽ 0.2, 0.4, 0.6, and 0.8.

Models of Tandem SH2 Domain Interactions

DISCUSSION
In vitro measurements using purified components are predicated on the notion that they are indicative of interactions in
cells, and they afford obvious advantages. However, when an
interaction involves more than one discrete step, and especially
when complexes of varying stoichiometry can form, the interpretation of the measurements can be challenging and perhaps
misleading. Reconciling data obtained using different assay
designs and platforms only adds to that challenge; here, we used
kinetic, rule-based models to accomplish this goal. Interactions
between the tandem SH2 domains of PI3K p85 regulatory subunit and its bisphosphorylated binding site in PDGF ␤-receptor
were analyzed in detail, and the cooperativity of the SH2
domains in forming a high avidity ring complex was evaluated
in terms of the concentration factor, . Analysis of SPR and ITC
measurements, which differ with respect to peptide configuration (immobilized versus soluble) and species concentrations

7344 JOURNAL OF BIOLOGICAL CHEMISTRY

VOLUME 283 • NUMBER 12 • MARCH 21, 2008

Downloaded from http://www.jbc.org/ at MISSOURI S&T on August 23, 2018

FIGURE 5. Effect of p85 dimerization on binding to immobilized, bisphosphorylated peptides. The calculations were performed using the immobilized phosphopeptide with p85 dimerization model (Model 4). Self-association of the dimerization domain in solution is characterized by a dissociation
constant KD,dimer ⫽ 1 M, and formation of Type II rings (Fig. 1C) is distinguished from other ring closure transitions by assignment of distinct  values,
SH2 and dimer, respectively (as explained in the text). KD values for the C-SH2
and N-SH2 domains are the same as in Figs. 2 and 4. A, equilibrium binding
isotherm of full-length p85, relative to C-SH2 or N-SH2 alone, with SH2 ⫽ 10
M and dimer varied as indicated. B, same as A, but with N-SH2 deleted from
p85; the value of dimer is varied as indicated.

(nanomolar versus micromolar), yielded a consistent order of
magnitude estimate of  ⫽ ⬃10 M. Significantly lower values
do not yield the effective KD values reported for tandem SH2
binding to Tyr(P)740/Tyr(P)751 (16, 18), nor do they give the
extent of inhibition observed in competition binding assays
(17). Significantly higher values promote ring formation even
when one of the components is in micromolar excess, in clear
disagreement with ITC measurements (18).
The estimate of  obtained for p85 tandem SH2 binding is 3
orders of magnitude lower than the value anticipated based on
simple search volume considerations, indicating significant
structural constraints. Consistent with this conclusion, a
worm-like chain model of peptide binding shows that consideration of the peptide flexibility alone can yield  values in the
low micromolar range (27). However, in experiments in which
the length of the peptide spacer sequence between Tyr(P) sites
was varied, peptide stimulation of PI3K kinase activity in vitro
was apparently able to tolerate a reduction of the spacing to 6
residues (33); based on this assertion, the worm-like chain
model produces a significantly higher estimate of  ⫽ ⬃10 mM
(27). It seems clear that factors other than peptide flexibility,
such as the conformational dynamics of the tandem SH2 construct (34) and the nature of the peptide residues flanking the
Tyr(P) sites (35) and other peptide residues, must contribute to
the structural constraints of the interaction.
Although still sufficient to enhance the binding of the tandem SH2 construct, the cooperativity of bisphosphorylated
peptide recognition is deemed to be relatively weak, which has
a number of implications for PI3K interactions with PDGF
receptors in cells. Absent from experiments with receptor-derived peptides are the activities of the receptor tyrosine kinase
and nonreceptor tyrosine kinases that associate with activated
receptors. That is significant because p85 is tyrosine-phosphorylated in cells stimulated with PDGF, on a site that engages the
N-SH2 domain (36, 37). Although it is presently unclear
whether or not that interaction is intramolecular (which might
lend further insights into the conformational dynamics of the
p85 SH2 domains), what is clear is that the role of the interaction is to relieve the autoinhibition of PI3K catalytic activity. In
our previous analysis of Shp2, which is regulated by its N-SH2
domain in a related fashion, it was shown that Shp2 phosphorylation and intramolecular N-SH2 binding gives rise to a
receptor binding avidity that lies between two extremes; one of
these is the case in which phosphorylation does not occur, and
the other is the case where the N-SH2 is completely buffered
from receptor binding (13). The modest value of  for p85/
receptor binding might represent a compromise between a
need for selective recognition of activated PDGF receptors, as
PI3K is recruited from the cytosol, and a need for displacement
of N-SH2 from the receptor after p85 is phosphorylated.
If the above is true, then the implication is that the N-SH2
domain does not contribute to PDGF receptor binding in cells
to the same extent as it does to binding of bisphosphorylated
peptide in vitro. Indeed, it has been shown that removing the
N-SH2 domain of p85 does not alter its binding to PDGF receptors, but intriguingly, neither does mutation of the phosphorylation site (36, 37), suggesting that the N-SH2 domain is dispensable for receptor binding. PI3K and PDGF receptor bind
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extraordinarily tightly (38), and PI3K signaling stimulated by
PDGF is saturated at much lower concentrations than is PDGF
receptor phosphorylation (39, 40), suggesting that interactions
other than C-SH2 binding to the receptor are required to stabilize the complex. Our model calculations show that p85
dimerization, whether by SH3 domain/proline-rich sequence
or N-SH2/phosphotyrosine interactions, could carry out this
function, in a manner that renders the N-SH2 domain dispensable. In the context of PDGF receptor binding in cells, it is
important to consider also the dimerization of PDGF receptors.
This configuration might contribute parallel binding sites for
the C-SH2 domains of two dimerized p85 molecules, such that
the complex is less structurally constrained than in the case of
binding to a single peptide or receptor molecule. Of course,
interactions of the SH3 and proline-rich motifs with other molecules (31), not to mention those of the catalytic subunit with
substrate and possibly other binding partners, could also contribute to the stability of PI3K recruitment in cells.
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